Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Open accessAbstract
SUMMARY While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole genome and transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor / 38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kilobases upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of structural variations were linked to distinct DNA repair deficiencies, suggesting their etiology, including associations of CDK12 mutation with tandem duplications, TP53 inactivation with inverted rearrangements and chromothripsis, and BRCA2 inactivation with deletions. Together, these observations provide a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most prostate cancers express AR throughout the course of the disease.
“Most PCas express AR throughout the course of the disease2–5”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
The Results section reports AR amplification in 70% of metastatic castration-resistant prostate cancer cases and associates it with elevated AR mRNA expression. That supports AR expression in many late-stage tumors, but the study sampled metastatic castration-resistant disease, not prostate cancers throughout their course; it does not establish expression across disease stages. (LLM, conf=0.80)
Experimental — accuracy not yet measuredThe androgen receptor (AR) is a critical/central driver of prostate cancer (PCa).
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
The Results (“A landscape of mutations and structural alterations,” page unavailable) report AR-related alterations in 85% of the metastatic castration-resistant prostate cancer samples, supporting AR’s importance in that setting. The claim refers to prostate cancer generally, while this paper’s findings concern its metastatic castration-resistant form. (LLM, conf=0.78)
Experimental — accuracy not yet measuredTumor alterations that reactivate AR signaling during treatment with an ARSI have been identified.
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
The Results section (“Duplications target AR, MYC, and FOXA1”; page not provided) identifies AR and upstream-enhancer amplifications associated with increased AR expression. The Discussion links enhancer amplification to resistance following first-line androgen deprivation therapy, but the Results say it was not associated with prior abiraterone or enzalutamide treatment. The paper therefore supports the identification of alterations that increase AR expression, not specifically their emergence during treatment with an ARSI. (LLM, conf=0.85)
Experimental — accuracy not yet measuredMechanisms of ARSI resistance include AR gene amplification, AR enhancer amplification, AR mutation, AR genomic structural rearrangements, AR splice variants and polymorphisms in androgen metabolism genes.
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
The Results sections “Structural variations disrupt key driver genes” and “Duplications target AR, MYC, and FOXA1” identify AR-region structural variation, including tandem duplications associated with increased AR expression. The latter section and the Discussion suggest a role in resistance to first-line androgen-deprivation therapy, but the paper says enhancer amplification was not associated with prior abiraterone or enzalutamide treatment. It therefore does not establish these rearrangements as a mechanism of resistance to those AR-signaling inhibitors. (LLM, conf=0.84)
Experimental — accuracy not yet measuredDeep deletions (primarily of BRCA2) occur much more frequently in prostate cancer (33%) compared to other cancer types.
“However, deep deletions (primarily of BRCA2; Supplementary Fig. 23) occurred much more frequently in prostate cancer (33%) compared to other cancer types, consistent with previous observations28.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [28]
The Results section, “A landscape of mutations and structural alterations” (page unavailable), reports BRCA2 inactivation and one deep deletion affecting MSH2 and MSH6. The Results section, “DNA repair defects drive SVs” (page unavailable), reports more deletions in tumors with biallelic BRCA2 mutations. Neither passage establishes that deep deletions are primarily of BRCA2, occur in 33% of prostate cancers, or are more frequent than in other cancer types; searches for those terms found no such comparison. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,706 · see citing works
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · see citing works
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · see citing works
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,380 · see citing works
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816 · see citing works
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Ohno, S. (1970) · doi:10.1007/978-3-642-86659-3 · Cited by 7,833 · see citing works
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,838 · see citing works
Recurrent Fusion of <i>TMPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · see citing works
Self-citationIntegrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,653 · see citing works
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645 · see citing works
Self-citationZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · see citing works
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A. A., Ahn, J., Akbani, R., Ally, A., Amin, S. B., Andry, C., Annala, M., Aprikian, A. G., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,082 · see citing works
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · see citing works
Histone modifications at human enhancers reflect global cell-type-specific gene expression
Heintzman, N. D., Hon, G. C., Hawkins, R. D., Kheradpour, P., Stark, A., Harp, L. F., Ye, Z., Lee, L. K., Stuart, R. K., Ching, C. W., et al. (2009) · Nature · doi:10.1038/nature07829 · Cited by 2,533 · see citing works
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · see citing works
Self-citationMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414 · see citing works
Circular binary segmentation for the analysis of array-based DNA copy number data
Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. H. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,256 · see citing works
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218 · see citing works
Self-citationDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · see citing works
Self-citationMutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909 · see citing works
Self-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C., Wala, J. A., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,843 · see citing works
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680 · see citing works
Self-citationStrelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,589 · see citing works
Self-citationWhole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,551 · see citing works
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · see citing works
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group, Gundem, G., Loo, P. V., Kremeyer, B., Alexandrov, L. B., Tubío, J. M. C., Papaemmanuil, E., Brewer, D. S., Kallio, H. M. L., Högnäs, G., et al. (2015) · Nature · doi:10.1038/nature14347 · Cited by 1,359 · see citing works
Punctuated Evolution of Prostate Cancer Genomes
Baca, S. C., Prandi, D., Lawrence, M. S., Mosquera, J. M., Romanel, A., Drier, Y., Park, K., Kitabayashi, N., MacDonald, T. Y., Ghandi, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.021 · Cited by 1,300 · see citing works
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257 · see citing works
Self-citationGeneHancer: genome-wide integration of enhancers and target genes in GeneCards
Fishilevich, S., Nudel, R., Rappaport, N., Hadar, R., Plaschkes, I., Stein, T. I., Rosen, N., Kohn, A., Twik, M., Safran, M., et al. (2017) · Database · doi:10.1093/database/bax028 · Cited by 1,219 · see citing works
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S., & Swanton, C. (2016) · Genome biology · doi:10.1186/s13059-016-0893-4 · Cited by 1,217 · see citing works
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., & Misawa, S. (1996) · PubMed · Cited by 1,162 · see citing works
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
Yeager, M., Orr, N., Hayes, R. B., Jacobs, K. B., Kraft, P., Wacholder, S., Minichiello, M. J., Fearnhead, P., Yu, K. F., Chatterjee, N., et al. (2007) · Nature Genetics · doi:10.1038/ng2022 · Cited by 1,122 · see citing works
Self-citationHRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086 · see citing works
Clock-like mutational processes in human somatic cells
Alexandrov, L. B., Jones, P. H., Wedge, D. C., Sale, J. E., Campbell, P. J., Nik‐Zainal, S., & Stratton, M. R. (2015) · Nature Genetics · doi:10.1038/ng.3441 · Cited by 1,038 · see citing works
Cingolani, P., Patel, V. M., Coon, M., Nguyen, T. T., Land, S. J., Ruden, D. M., & Lu, X. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00035 · Cited by 1,012 · see citing works
RCircos: an R package for Circos 2D track plots
Zhang, H., Meltzer, P. S., & Davis, S. R. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-244 · Cited by 995 · see citing works
Jones, D., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 938 · see citing works
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S., Laxman, B., Dhanasekaran, S., Helgeson, B. E., Cao, X.-H., Morris, D. S., Menon, A., Jing, X.-J., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 904 · see citing works
Self-citationTranscriptome sequencing to detect gene fusions in cancer
Maher, C. A., Kumar‐Sinha, C., Cao, X., Sundaram, S. K., Han, B., Jing, X., Sam, L. T., Barrette, T. R., Palanisamy, N., & Chinnaiyan, A. M. (2009) · Nature · doi:10.1038/nature07638 · Cited by 887 · see citing works
Self-citationThe long tail of oncogenic drivers in prostate cancer
PCF/SU2C International Prostate Cancer Dream Team, Armenia, J., Wankowicz, S. A. M., Liu, D., Gao, J., Kundra, R., Reznik, E., Chatila, W. K., Chakravarty, D., Han, G. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0078-z · Cited by 873 · see citing works
Self-citationKarantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866 · see citing works
Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865 · see citing works
A common variant associated with prostate cancer in European and African populations
Amundadottir, L. T., Sulem, P., Gudmundsson, J., Helgason, A., Baker, A., Agnarsson, B. A., Sigurdsson, A., Benediktsdottir, K. R., Cazier, J.-B., Sainz, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1808 · Cited by 787 · see citing works
Signatures of mutation and selection in the cancer genome
Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08768 · Cited by 707 · see citing works
Prensner, J. R., Iyer, M. K., Sahu, A., Asangani, I. A., Cao, Q., Patel, L. R., Vergara, I. A., Davicioni, E., Erho, N., Ghadessi, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2771 · Cited by 669 · see citing works
Self-citationGenomic hallmarks of localized, non-indolent prostate cancer
Fraser, M. E., Sabelnykova, V. Y., Yamaguchi, T. N., Heisler, L. E., Livingstone, J. M., Huang, V., Shiah, Y.-J., Yousif, F., Lin, X., Masella, A. P., et al. (2017) · Nature · doi:10.1038/nature20788 · Cited by 589 · see citing works
Self-citationPolak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G., Rosebrock, D., Livitz, D., Kübler, K., Mouw, K. W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3934 · Cited by 531 · see citing works
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M. V., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 450 · see citing works
Tutt, A. N. J., Bertwistle, D., Valentine, J., Gabriel, A., Swift, S., Ross, G., Griffin, C. S., Thacker, J., & Ashworth, A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4704 · Cited by 429 · see citing works
Self-citationIsaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms
Raczy, C., Petrovski, R., Saunders, C. T., Chorny, I., Kruglyak, S., Margulies, E. H., Chuang, H., Källberg, M., Kumar, S. A., Liao, A. K., et al. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt314 · Cited by 333 · see citing works
Self-citationSomaticSignatures: inferring mutational signatures from single-nucleotide variants
Gehring, J. S., Fischer, B., Lawrence, M. F., & Huber, W. K. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv408 · Cited by 307 · see citing works
Self-citationGenomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Wang, Y. K., Bashashati, A., Anglesio, M. S., Cochrane, D. R., Grewal, D. S., Ha, G., McPherson, A., Horlings, H. M., Senz, J., Prentice, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3849 · Cited by 273 · see citing works
The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc
Prensner, J. R., Chen, W., Han, S., Iyer, M. K., Cao, Q., Kothari, V., Evans, J. R., Knudsen, K. E., Paulsen, M. T., Ljungman, M. E., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.001 · Cited by 257 · see citing works
Self-citationFragile sites in cancer: more than meets the eye
Glover, T. W., Wilson, T. E., & Arlt, M. F. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.52 · Cited by 247 · see citing works
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
CAMCAP Study Group, Wedge, D. C., Gundem, G., Mitchell, T., Woodcock, D. J., Martincorena, I., Ghori, M., Zamora, J., Butler, A. P., Whitaker, H. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0086-z · Cited by 225 · see citing works
CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer
Burkhardt, L., Fuchs, S., Krohn, A., Masser, S., Mäder, M., Kluth, M., Bachmann, F., Huland, H., Steuber, T. P., Graefen, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1342 · Cited by 214 · see citing works
Canvas: versatile and scalable detection of copy number variants
Roller, E., Ivakhno, S., Lee, S., Royce, T., & Tanner, S. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw163 · Cited by 206 · see citing works
Blattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204 · see citing works
Self-citationKron, K. J., Murison, A. J., Zhou, S., Huang, V., Yamaguchi, T. N., Shiah, Y.-J., Fraser, M. E., van der Kwast, T., Boutros, P. C., Bristow, R. G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3930 · Cited by 184 · see citing works
Chromothripsis and Human Disease: Piecing Together the Shattering Process
Maher, C. A., & Wilson, R. K. (2012) · Cell · doi:10.1016/j.cell.2012.01.006 · Cited by 159 · see citing works
Self-citationPopova, T., Manié, E., Boeva, V., Battistella, A., Goundiam, O., Smith, N. K., Mueller, C. R., Raynal, V., Mariani, O., Sastre-Garau, X., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2128 · Cited by 130 · see citing works
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 127 · see citing works
Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness
Huang, S., Gulzar, Z. G., Salari, K., Lapointe, J., Brooks, J. D., & Pollack, J. R. (2011) · Oncogene · doi:10.1038/onc.2011.590 · Cited by 108 · see citing works
The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer
Prensner, J. R., Sahu, A., Iyer, M. K., Malik, R., Chandler, B. C., Asangani, I. A., Poliakov, A., Vergara, I. A., Alshalalfa, M., Jenkins, R. B., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1846 · Cited by 100 · see citing works
Self-citationHeterogeneity in the inter-tumor transcriptome of high risk prostate cancer
Wyatt, A. W., Mo, F., Wang, K., McConeghy, B., Brahmbhatt, S., Jong, L., Mitchell, D. M., Johnston, R. L., Haegert, A., Li, E., et al. (2014) · Genome Biology · doi:10.1186/s13059-014-0426-y · Cited by 82 · see citing works
Self-citationSpritzer, C. E., Afonso, P. D., Vinson, E. N., Turnbull, J. D., Morris, K. K., Foye, A., Madden, J. F., Choudhury, K. R., Febbo, P. G., & George, D. J. (2013) · Radiology · doi:10.1148/radiol.13121782 · Cited by 64 · see citing works
Self-citationHolmes, M. G., Foss, E. W., Joseph, G. B., Foye, A., Beckett, B. R., Motamedi, D., YOUNGREN, J. F., THOMAS, G. V., Huang, J., Aggarwal, R. R., et al. (2017) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2017.04.019 · Cited by 38 · see citing works
Self-citationAggarwal, R. R., Beer, T. M., Gleave, M. E., Stuart, J. M., Rettig, M. B., Evans, C. P., YOUNGREN, J. F., Alumkal, J. J., Huang, J., THOMAS, G. V., et al. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.10.011 · Cited by 14 · see citing works
Self-citation
Flagged first, then by citations
1 of the 73 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372 · see citing works
Self-citationA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743 · see citing works
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658 · see citing works
Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R. J., Syndikus, I., Ralph, C., Jain, S., Varughese, M. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30684-9 · Cited by 634 · see citing works
Structural variation in the sequencing era
Ho, S. S., Urban, A. E., & Mills, R. E. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0180-9 · Cited by 608 · see citing works
Sandhu, S. K., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 610 · see citing works
Pan-cancer landscape of homologous recombination deficiency.
Nguyen, L., W. M. Martens, J., Van Hoeck, A., & Cuppen, E. (2020) · Nature communications · doi:10.1038/s41467-020-19406-4 · Cited by 532 · see citing works
“However, deep deletions (primarily of BRCA2; Supplementary figure 20) occurred much more frequently in prostate cancer (33%) compared to other cancer types, consistent with previous observations[29].”
Genomic and phenotypic heterogeneity in prostate cancer
Haffner, M. C., Zwart, W. T., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., Marzo, A. M. D., Nelson, P. S., & Yegnasubramanian, S. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00400-w · Cited by 520 · see citing works
Safran, M., Rosen, N., Twik, M., Barshir, R., Stein, T. I., Dahary, D., Fishilevich, S., & Lancet, D. (2021) · Springer eBooks · doi:10.1007/978-981-16-5812-9_2 · Cited by 493 · see citing works
Biologically informed deep neural network for prostate cancer discovery
Elmarakeby, H. A., Hwang, J., Arafeh, R., Crowdis, J., Gang, S., Liu, D., AlDubayan, S. H., Salari, K., Kregel, S., Richter, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03922-4 · Cited by 456 · see citing works
Hormonal Therapy for Prostate Cancer
Desai, K. B., McManus, J. M., & Sharifi, N. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab002 · Cited by 461 · see citing works
Androgen receptor activity in T cells limits checkpoint blockade efficacy
Guan, X., Polesso, F., Wang, C., Sehrawat, A., Hawkins, R. M., Murray, S., THOMAS, G. V., Caruso, B., Thompson, R. F., Wood, M. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04522-6 · Cited by 396 · see citing works
Self-citationThe DNA methylation landscape of advanced prostate cancer
Zhao, S. G., Chen, W. S., Li, H., Foye, A., Zhang, M., Sjöström, M., Aggarwal, R. R., Playdle, D., Liao, A. K., Alumkal, J. J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0648-8 · Cited by 351 · see citing works
Self-citationA genomic and epigenomic atlas of prostate cancer in Asian populations
Li, J., Xu, C., Lee, H. J., Ren, S., Zi, X., Zhang, Z., Wang, H., Yu, Y., Yang, C., Gao, X., et al. (2020) · Nature · doi:10.1038/s41586-020-2135-x · Cited by 343 · see citing works
Netto, G. J., Amin, M. B., Berney, D. M., Compérat, É., Gill, A. J., Hartmann, A., Menon, S. G., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.002 · Cited by 316 · see citing works
Brady, L., Kriner, M., Coleman, I. M., Morrissey, C. M., Roudier, M. P., True, L. D., Gulati, R., Plymate, S. R., Zhou, Z., Birditt, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21615-4 · Cited by 301 · see citing works
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y.-C., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 292 · see citing works
Self-citationNyquist, M. D., Corella, A. N., Coleman, I. M., Sarkar, N. D., Kaipainen, A., Ha, G., Gulati, R., Ang, L. S., Chatterjee, P., Lucas, J. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107669 · Cited by 290 · see citing works
Mutational signatures: emerging concepts, caveats and clinical applications
Koh, C. C., Degasperi, A., Zou, X., Momen, S., & Nik‐Zainal, S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00377-7 · Cited by 276 · see citing works
Zhang, C., Zhang, M., Ge, S., Huang, W., Lin, X., Gao, J. X., Gong, J., & Shen, L. (2019) · Cancer Medicine · doi:10.1002/cam4.2360 · Cited by 283 · see citing works
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 266 · see citing works
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 281 · see citing works
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W. M., Linton, E. L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 259 · see citing works
Su, W., Han, H. H., Wang, Y., Zhang, B., Zhou, B., Cheng, Y., Rumandla, A., Gurrapu, S., Chakraborty, G., Su, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.009 · Cited by 242 · see citing works
Towards precision oncology in advanced prostate cancer
Ku, S., Gleave, M. E., & Beltran, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0237-8 · Cited by 232 · see citing works
Self-citationvan Dessel, L. F., van Riet, J., Smits, M., Zhu, Y., Hamberg, P., van der Heijden, M. S., Bergman, A. M., van Oort, I. M., de Wit, R., Voest, E. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13084-7 · Cited by 209 · see citing works
Beltran, H., Romanel, A., Conteduca, V., Casiraghi, N. A., Sigouros, M., Franceschini, G. M., Orlando, F., Fedrizzi, T., Ku, S., Dann, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131041 · Cited by 195 · see citing works
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q. F., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 197 · see citing works
Complexities of Prostate Cancer
Wasim, S., Lee, S., & Kim, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214257 · Cited by 210 · see citing works
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Vandekerkhove, G. R., Struss, W. J., Annala, M., Kallio, H. M. L., Khalaf, D. J., Warner, E. W., Herberts, C., Ritch, E. J., Beja, K., Loktionova, Y., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.12.042 · Cited by 185 · see citing works
Self-citationDeep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Herberts, C., Annala, M., Sipola, J., Ng, S. W. S., Chen, X. E., Nurminen, A., Korhonen, O. V., Munzur, A. D., Beja, K., Schönlau, E., et al. (2022) · Nature · doi:10.1038/s41586-022-04975-9 · Cited by 186 · see citing works
Self-citationStopsack, K. H., Nandakumar, S., Wibmer, A. G., Haywood, S., Weg, E. S., Barnett, E. S., Kim, C. J., Carbone, E. A., Vasselman, S. E., Nguyen, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0168 · Cited by 181 · see citing works
Pioneer of prostate cancer: past, present and the future of FOXA1
Teng, M., Zhou, S., Cai, C., Lupien, M., & He, H. H. (2020) · Protein & Cell · doi:10.1007/s13238-020-00786-8 · Cited by 179 · see citing works
Self-citationThe landscape of chromothripsis across adult cancer types
Voronina, N., Wong, J., Hübschmann, D., Hlevnjak, M., Uhrig, S., Heilig, C. E., Horak, P., Kreutzfeldt, S., Möck, A., Stenzinger, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16134-7 · Cited by 168 · see citing works
Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention
Vietri, M. T., D’Elia, G., Caliendo, G., Resse, M., Casamassimi, A., Passariello, L., Albanese, L., Cioffi, M., & Molinari, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073753 · Cited by 171 · see citing works
Discovering dominant tumor immune archetypes in a pan-cancer census
Combes, A. J., Samad, B., Tsui, J. L., Chew, N. W., Yan, P., Reeder, G. C., Kushnoor, D., Shen, A. S., Davidson, B. R., Barczak, A. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.004 · Cited by 163 · see citing works
Self-citationTargeting the Androgen Signaling Axis in Prostate Cancer
Dai, C. S., Dehm, S. M., & Sharifi, N. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00433 · Cited by 172 · see citing works
Self-citationBiomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Carreira, S., Porta, N., Arce‐Gallego, S., Seed, G., Llop‐Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C. M., Baker, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0007 · Cited by 160 · see citing works
Golan, T., O'Kane, G. M., Denroche, R. E., Raitses‐Gurevich, M., Grant, R. C., Holter, S., Wang, Y., Zhang, A. X. W., Jang, G. H., Stossel, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.220 · Cited by 155 · see citing works
Landscape of Noncoding RNA in Prostate Cancer
Hua, J. T., Chen, S., & He, H. H. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.08.004 · Cited by 151 · see citing works
Self-citationCellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 156 · see citing works
Alumkal, J. J., Sun, D., Lu, E., Beer, T. M., THOMAS, G. V., Latour, E. J., Aggarwal, R. R., Cetnar, J. P., Ryan, C. J., Tabatabaei, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922207117 · Cited by 145 · see citing works
Self-citationComprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System
Yachida, S., Totoki, Y., Noë, M., Nakatani, Y., Horie, M., Kawasaki, K., Nakamura, H., Saito-Adachi, M., Suzuki, M., Takai, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0669 · Cited by 119 · see citing works
The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer
Lancho, O., & Herranz, D. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.10.003 · Cited by 137 · see citing works
Rubin, M. A., Bristow, R. G., Thienger, P., Dive, C., & Imielinski, M. B. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.033 · Cited by 136 · see citing works
Kohli, M., Tan, W. W., Zheng, T., Wang, A., Montesinos, C., Wong, C., Du, P., Jia, S., Yadav, S., Horvath, L. G., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102728 · Cited by 137 · see citing works
Aggarwal, R. R., Schweizer, M. T., Nanus, D. M., Pantuck, A. J., Heath, E. I., Campeau, E., Attwell, S., Norek, K., Snyder, M., Bauman, L. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1707 · Cited by 136 · see citing works
Self-citationChen, W. S., Aggarwal, R. R., Zhang, L., Zhao, S. G., THOMAS, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.020 · Cited by 130 · see citing works
Self-citationBiological Evolution of Castration-resistant Prostate Cancer
Davies, A., Conteduca, V., Zoubeidi, A., & Beltran, H. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.01.016 · Cited by 125 · see citing works
Self-citationATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer
Rafiei, S., Fitzpatrick, K., Liu, D., Cai, M.-Y., Elmarakeby, H., Park, J., Ricker, C. A., Kochupurakkal, B. S., Choudhury, A. D., Hahn, W. C., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3126 · Cited by 125 · see citing works
Taavitsainen, S., Engedal, N., Cao, S., Handle, F., Erickson, A. M., Preković, S., Wetterskog, D., Tolonen, T. T., Vuorinen, E. M., Kiviaho, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25624-1 · Cited by 124 · see citing works
NSD2 is a conserved driver of metastatic prostate cancer progression
Aytés, À., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J. M., Palomero, L., Farran-Matas, S., Rubin, M. A., Shen, M. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07511-4 · Cited by 119 · see citing works
Computational analysis of cancer genome sequencing data
Cortés‐Ciriano, I., Gulhan, D., Lee, J. J.-K., Melloni, G. E. M., & Park, P. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00431-y · Cited by 116 · see citing works
Ramnarine, V. R., Kobelev, M., Gibb, E. A., Nouri, M., Lin, D., Wang, Y. Z., Buttyan, R., Davicioni, E., Zoubeidi, A., & Collins, C. C. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.040 · Cited by 119 · see citing works
Self-citationNguyen, B., Mota, J. M., Nandakumar, S., Stopsack, K. H., Weg, E. S., Rathkopf, D. E., Morris, M. J., Scher, H. I., Kantoff, P. W., Gopalan, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.024 · Cited by 120 · see citing works
Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
Le, T. K., Duong, Q. H., Baylot, V., Fargette, C., Baboudjian, M., Colleaux, L., Taïeb, D., & Rocchi, P. (2023) · Cancers · doi:10.3390/cancers15205047 · Cited by 121 · see citing works
Yuan, J., Kensler, K. H., Hu, Z., Zhang, Y., Zhang, T., Jiang, J., Xu, M., Pan, Y., Long, M., Montone, K. T., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008641 · Cited by 116 · see citing works
Self-citationSignificance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Chakraborty, G., Armenia, J., Mazzu, Y. Z., Nandakumar, S., Stopsack, K. H., Atiq, M. O., Komura, K., Jehane, L. E., Hirani, R., Chadalavada, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1570 · Cited by 114 · see citing works
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
Reimers, M. A., Yip, S., Zhang, L., Cieslik, M. P., Dhawan, M., Montgomery, B., Wyatt, A. W., Chi, K. N., Small, E. J., Chinnaiyan, A. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.036 · Cited by 113 · see citing works
Self-citationComprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System
Yachida, S., Totoki, Y., Noë, M., Nakatani, Y., Horie, M., Kawasaki, K., Nakamura, H. K., Saito-Adachi, M., Suzuki, M., Takai, E., et al. (2022) · Utrecht University Repository (Utrecht University) · Cited by 112 · see citing works
Wang, M., Chen, J., Lu, Y., Bawcom, A. R., Wu, J., Ou, J., Asara, J. M., Armstrong, A. J., Wang, Q., Li, L., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166647 · Cited by 113 · see citing works
Self-citationMerging new-age biomarkers and nanodiagnostics for precision prostate cancer management
Koo, K. M., Mainwaring, P. N., Tomlins, S. A., & Trau, M. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0178-2 · Cited by 111 · see citing works
Self-citationLotan, T. L., Kaur, H. B., Salles, D. C., Murali, S., Schaeffer, E. M., Lanchbury, J. S. S., Isaacs, W. B., Brown, R. E., Richardson, A. L., Cussenot, O., et al. (2021) · Modern Pathology · doi:10.1038/s41379-020-00731-4 · Cited by 108 · see citing works
Oligometastatic prostate cancer: Reality or figment of imagination?
Foster, C. C., Weichselbaum, R. R., & Pitroda, S. P. (2018) · Cancer · doi:10.1002/cncr.31860 · Cited by 105 · see citing works
Zhu, Y., Dalrymple, S. L., Coleman, I. M., Zheng, S. L., Xu, J., Hooper, J. E., Antonarakis, E. S., Marzo, A. M. D., Meeker, A. K., Nelson, P. S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01479-6 · Cited by 104 · see citing works
Genome-wide plasma DNA methylation features of metastatic prostate cancer
Wu, A., Cremaschi, P., Wetterskog, D., Conteduca, V., Franceschini, G. M., Kleftogiannis, D., Jayaram, A., Sandhu, S. K., Wong, S. Q., Benelli, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130887 · Cited by 103 · see citing works
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 99 · see citing works
Homologous Recombination and the Formation of Complex Genomic Rearrangements
Piazza, A., & Heyer, W. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.10.006 · Cited by 102 · see citing works
Sztupinszki, Z. M., Dióssy, M., Krzystanek, M., Börcsök, J., Pomerantz, M. M., Tisza, V., Spisák, S., Rusz, O., Csabai, I., Freedman, M. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2135 · Cited by 102 · see citing works
Whole-genome landscape of adult T-cell leukemia/lymphoma
Kogure, Y., Kameda, T., Koya, J., Yoshimitsu, M., Nosaka, K., Yasunaga, J., Imaizumi, Y., Watanabe, M., Saito, Y., Ito, Y., et al. (2021) · Blood · doi:10.1182/blood.2021013568 · Cited by 100 · see citing works
Annala, M., Taavitsainen, S., Khalaf, D. J., Vandekerkhove, G. R., Beja, K., Sipola, J., Warner, E. W., Herberts, C., Wong, A., Fu, S. Y. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1625 · Cited by 95 · see citing works
Self-citationSnyder, L. B., Neklesa, T. K., Willard, R. R., Gordon, D., Pizzano, J., Vitale, N., Robling, K., Dorso, M. A., Moghrabi, W. N., Landrette, S. F., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0655 · Cited by 97 · see citing works
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V. M., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., THOMAS, G. V., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0134-5 · Cited by 96 · see citing works
Self-citationStructural Variation in Cancer: Role, Prevalence, and Mechanisms
Cosenza, M. R., Rodríguez–Martín, B., & Korbel, J. O. (2022) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-120121-101149 · Cited by 92 · see citing works
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Sugawara, T., Baumgart, S. J., Nevedomskaya, E., Reichert, K., Steuber, H., Lejeune, P., Mumberg, D., & Haendler, B. (2019) · International Journal of Cancer · doi:10.1002/ijc.32242 · Cited by 92 · see citing works
Targeting Nuclear Receptors with PROTAC degraders
Flanagan, J. J., & Neklesa, T. K. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110452 · Cited by 97 · see citing works
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
He, Y., Wei, T., Ye, Z., Orme, J. J., Lin, D., Sheng, H., Fazli, L., Karnes, R. J., Jiménez, R. E., Wang, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21860-7 · Cited by 92 · see citing works
Self-citationActivating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
Herberts, C., Murtha, A. J., Fu, S. Y. F., Wang, G., Schönlau, E., Xue, H., Lin, D., Gleave, A., Yip, S., Angeles, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.058 · Cited by 90 · see citing works
Self-citationHawley, J. E., Obradović, A., Dallos, M. C., Lim, E. A., Runcie, K. D., Ager, C. R., McKiernan, J., Anderson, C. B., DeCastro, G. J., Weintraub, J. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.006 · Cited by 92 · see citing works
Illuminating the noncoding genome in cancer
Zhang, X., & Meyerson, M. M. (2020) · Nature Cancer · doi:10.1038/s43018-020-00114-3 · Cited by 85 · see citing works
Warner, E. W., Herberts, C., Fu, S. Y. F., Yip, S., Wong, A., Wang, G., Ritch, E. J., Murtha, A. J., Vandekerkhove, G. R., Fonseca, N. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3708 · Cited by 88 · see citing works
Self-citationDeLucia, D. C., Cardillo, T. M., Ang, L. S., Labrecque, M. P., Zhang, A., Hopkins, J. E., Sarkar, N. D., Coleman, I. M., da Costa, R. M. G., Corey, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3396 · Cited by 85 · see citing works
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Lundberg, A., Zhang, M., Aggarwal, R. R., Li, H., Zhang, L., Foye, A., Sjöström, M., Chou, J., Chang, K. C., Moreno-Rodriguez, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0593 · Cited by 85 · see citing works
Self-citationA systematic review of the prevalence of DNA damage response gene mutations in prostate cancer
Lang, S., Swift, S. L., White, H., Misso, K., Kleijnen, J., & Quek, R. G. W. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4842 · Cited by 83 · see citing works
Linder, S., Hoogstraat, M., Stelloo, S., Eickhoff, N., Schuurman, K. G., de Barros, H. A., Alkemade, M., Bekers, E. M., Severson, T., Sanders, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0576 · Cited by 84 · see citing works
Self-citationLi, Y., Yang, R., Henzler, C. M., Ho, Y., Passow, C. N., Auch, B., Carreira, S., Rodrigues, D. N., Bertan, C. M., Hwang, T. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3023 · Cited by 83 · see citing works
Self-citationMolecular mechanisms underlying the development of neuroendocrine prostate cancer
Liu, S., Alabi, B. R., Yin, Q., & Stoyanova, T. I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.007 · Cited by 83 · see citing works
Aggarwal, R. R., Quigley, D. A., Huang, J., Zhang, L., Beer, T. M., Rettig, M. B., Reiter, R. E., Gleave, M. E., THOMAS, G. V., Foye, A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1101 · Cited by 80 · see citing works
Self-citationMalihi, P. D., Graf, R. P., Rodríguez, Á., Ramesh, N., Lee, J. S. H., Sutton, R., Jiles, R., Velasco, C. R., Sei, E., Kolatkar, A. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4100 · Cited by 78 · see citing works
Prostate zones and cancer: lost in transition?
Ali, A., Feu, A. D., Oliveira, P., Choudhury, A., Bristow, R. G., & Baena, E. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00524-7 · Cited by 79 · see citing works
CDK12: A Potent Target and Biomarker for Human Cancer Therapy
Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020) · Cells · doi:10.3390/cells9061483 · Cited by 75 · see citing works
Xu, L., Yin, Y., Li, Y., Chen, X., Chang, Y., Zhang, H., Liu, J., Beasley, J., McCaw, P., Zhang, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012748118 · Cited by 78 · see citing works
Self-citationTechnical and biological constraints on ctDNA-based genotyping
Herberts, C., & Wyatt, A. W. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.06.001 · Cited by 78 · see citing works
Self-citationEftekharzadeh, B., Banduseela, V. C., Chiesa, G., Martínez-Cristóbal, P., Rauch, J. N., Nath, S. R., Schwarz, D. M. C., Shao, H., Marin-Argany, M., Di Sanza, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11594-y · Cited by 76 · see citing works
Ritch, E. J., Fu, S. Y. F., Herberts, C., Wang, G., Warner, E. W., Schönlau, E., Taavitsainen, S., Murtha, A. J., Vandekerkhove, G. R., Beja, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1623 · Cited by 75 · see citing works
Self-citationAndrogen receptor and MYC equilibration centralizes on developmental super-enhancer
Guo, H., Wu, Y., Nouri, M., Spisák, S., Russo, J. W., Sowalsky, A. G., Pomerantz, M. M., Wei, Z., Korthauer, K. D., Seo, J.-H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27077-y · Cited by 73 · see citing works
Self-citationHan, H. H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110595 · Cited by 72 · see citing works
Accelerating precision medicine in metastatic prostate cancer
Mateo, J., McKay, R. R., Abida, W. M., Aggarwal, R. R., Alumkal, J. J., Alva, A. S., Feng, F. Y.-C., Gao, X. Y., Graff, J. N., Hussain, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00141-0 · Cited by 74 · see citing works
Self-citationWang, T.-Y., Liu, Q., Ren, Y., Alam, S. K., Wang, L., Zhu, Z., Hoeppner, L. H., Dehm, S. M., Cao, Q., & Yang, R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.028 · Cited by 74 · see citing works
Self-citationWang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed Central · Cited by 73 · see citing works
- Authors
- Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. M., Thomas, G., Chi, K. N., Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J., & Feng, F. Y.
- Affiliations
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- University of Michigan (US)
- Oregon Health & Science University (US)
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- University of California, Los Angeles (US)
- University of Minnesota (US)
- University of California Davis Medical Center (US)
- University of California, Santa Cruz (US)
- Illumina (United States) (US)
- Thomas Jefferson University (US)
- University Health Network (CA)
- Duke University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Chinnaiyan, Arul M.
- Maher, Christopher A.
- Small, Eric J.
- Feng, Felix Y.
- ORCID
- Quigley, David A.
- Dang, Ha X.
- Zhao, Shuang G.
- Lloyd, Paul
- Aggarwal, Rahul
- Alumkal, Joshi J.
- Foye, Adam
- Kothari, Vishal
- Perry, Marc D.
- Zhang, Li
- Zhang, Jin
- Youngren, Jack F.
- Cieslik, Marcin P.
- Parolia, Abhijit
- Beer, Tomasz M.
- Thomas, George
- Chi, Kim N.
- Gleave, Martin
- Lack, Nathan A.
- Zoubeidi, Amina
- Reiter, Robert E.
- Rettig, Matthew B.
- Witte, Owen
- Ryan, Charles J.
- Fong, Lawrence
- Kim, Won
- Friedlander, Terence
- Chou, Jonathan
- Li, Haolong
- Das, Rajdeep
- Li, Hui
- Goodarzi, Hani
- Gilbert, Luke A.
- Lara, Primo N.
- Evans, Christopher P.
- Goldstein, Theodore C.
- Stuart, Joshua M.
- Tomlins, Scott A.
- Spratt, Daniel E.
- Farh, Kyle
- Gehring, Julian S.
- Hakenberg, Jörg
- Shon, John
- Sickler, Brad
- Batzoglou, Serafim
- Knudsen, Karen E.
- He, Housheng H.
- Huang, Jiaoti
- Wyatt, Alexander W.
- Dehm, Scott M.
- Ashworth, Alan
- Chinnaiyan, Arul M.
- Maher, Christopher A.
- Small, Eric J.
- Feng, Felix Y.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 174
- Issue
- 3
- Pages
- 758-769.e9
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6425931
- OpenAlex
- W2884001931
- Semantic Scholar
- c72ffe522bd85597687b47e4d3db90ec72b4fc80
- Cited by
- 733
- References
- 73
- Citations by year
- 2026: 48 · 2025: 73 · 2024: 102 · 2023: 107 · 2022: 94 · 2021: 110 · 2020: 102 · 2019: 81 · 2018: 15
- FWCI
- 58.02
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-10-18)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Stand Up To Cancer-Prostate Cancer Foundation Prostate Cancer Dream Team Award (SU2C-AACR-DT0812, SU2C-AACR-DT0712)
- Movember Foundation
- Goldberg-Benioff Research Fund for Prostate Cancer Translational Biology
- Prostate Cancer Foundation Challenge
- V Foundation
- BRCA Foundation Young Investigator Award
- Department of Defense (W81XWH-16-1-0747, W81XWH-15-1-0562, PC160429, W81XWH-17-1-0192)
- Early Detection Research Network (U01 CA214170)
- Prostate SPORE (P50 CA186786, P50 CA097186)
- NIH (R01CA174777)
- NCI T32 (CA108462)
- Prostate Cancer Foundation Young Investigator Awards
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, structural variants, androgen receptor, c-Myc, tandem duplication, long non-coding RNA, DNA repair deficiency, CDK12, TP53, chromothripsis, BRCA2
- MeSH terms
- Whole Genome Sequencing, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Prostatic Neoplasms, Receptors, Androgen, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-myc, Cyclin-Dependent Kinases, Tandem Repeat Sequences, Gene Expression Profiling, Genomics, BRCA2 Protein, Genomic Structural Variation, DNA Copy Number Variations, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
